Scripps' two big research outfits in California and Florida have allied themselves with the J&J Innovation Center in Menlo Park, CA, in an effort designed to take some of their early-stage breakthroughs and spin off new development programs, looking to kick-start a few biotech startups and Big Pharma match-ups along the way.
Three years ago, Sanofi walked away from a $375 million diabetes partnership with Metabolex, which had just salved the wound with a new pact with J&J. Now, operating under a new name--CymaBay--and armed with a fresh $38 million raise from late last year, the small biotech is floating plans for a $30 million IPO, looking to cash in on the lingering biotech boom.
Johnson & Johnson and Bayer's Xarelto made its way to the front of the new-age anticoagulant pack not long after hitting the U.S. market, gaining ground from rival Pradaxa to head what has since become a three-horse race. And that's ground its makers aren't ready to cede.
A Johnson & Johnson number cruncher says nuggets of marketing gold are waiting to be found on its parenting site BabyCenter.
Johnson & Johnson is using a research panel of 50,000 consumers, together with sharing-minded mothers on its parenting site BabyCenter, to flag ideas and catchphrases that resonate with moms.
Johnson & Johnson's Ethicon arm has been ordered to pay $1.2 million in damages in a trial alleging it produced faulty vaginal mesh that was implanted into a 64-year-old woman.
Johnson & Johnson has formally accepted the Carlyle Group's $4 billion-plus bid to snatch up its Ortho Clinical Diagnostics arm, more than two months after announcing the proposed transaction.
Denmark's Genmab is rolling right along with breakthrough-designated daratumumab for double refractory multiple myeloma, hitting a milestone in Phase II development and triggering a $22 million payout from collaborator Johnson & Johnson.
It's bad news for Johnson and Johnson's Ethicon division in its ongoing vaginal mesh saga: The company paid out $11.1 million to settle one of the first of many cases to go to court over its transvaginal mesh products, Lawyers and Settlements reported.
GlaxoSmithKline announced today that bottles of its alli over-the-counter weight-loss drug were tampered with, and warned consumers to look out for suspect packages.